nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—ADRA2A—type 2 diabetes mellitus	0.144	0.521	CbGaD
Loxapine—HTR2C—type 2 diabetes mellitus	0.133	0.479	CbGaD
Loxapine—DRD5—Bromocriptine—type 2 diabetes mellitus	0.0482	0.109	CbGbCtD
Loxapine—HTR7—Bromocriptine—type 2 diabetes mellitus	0.0354	0.0801	CbGbCtD
Loxapine—DRD4—Bromocriptine—type 2 diabetes mellitus	0.0344	0.0779	CbGbCtD
Loxapine—HTR6—Bromocriptine—type 2 diabetes mellitus	0.031	0.0702	CbGbCtD
Loxapine—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.0283	0.0641	CbGbCtD
Loxapine—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.0271	0.0614	CbGbCtD
Loxapine—DRD3—Bromocriptine—type 2 diabetes mellitus	0.0256	0.0579	CbGbCtD
Loxapine—DRD1—Bromocriptine—type 2 diabetes mellitus	0.0246	0.0558	CbGbCtD
Loxapine—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.0246	0.0558	CbGbCtD
Loxapine—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0234	0.0529	CbGbCtD
Loxapine—ADRB1—Bromocriptine—type 2 diabetes mellitus	0.0212	0.0481	CbGbCtD
Loxapine—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0198	0.0447	CbGbCtD
Loxapine—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.018	0.0408	CbGbCtD
Loxapine—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.017	0.0385	CbGbCtD
Loxapine—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0163	0.0368	CbGbCtD
Loxapine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0163	0.0368	CbGbCtD
Loxapine—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0156	0.0353	CbGbCtD
Loxapine—DRD2—Bromocriptine—type 2 diabetes mellitus	0.015	0.0339	CbGbCtD
Loxapine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00216	0.0615	CbGeAlD
Loxapine—HTR7—sympathetic nervous system—type 2 diabetes mellitus	0.00208	0.0593	CbGeAlD
Loxapine—HTR2A—arteriole—type 2 diabetes mellitus	0.00203	0.0581	CbGeAlD
Loxapine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00145	0.0414	CbGeAlD
Loxapine—HTR7—autonomic nervous system—type 2 diabetes mellitus	0.0014	0.0399	CbGeAlD
Loxapine—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.0013	0.037	CbGeAlD
Loxapine—DRD1—nerve—type 2 diabetes mellitus	0.00126	0.0359	CbGeAlD
Loxapine—HTR3A—nerve—type 2 diabetes mellitus	0.00121	0.0347	CbGeAlD
Loxapine—HTR1B—artery—type 2 diabetes mellitus	0.00103	0.0293	CbGeAlD
Loxapine—SLC6A3—nerve—type 2 diabetes mellitus	0.00101	0.0288	CbGeAlD
Loxapine—HTR7—peripheral nervous system—type 2 diabetes mellitus	0.00101	0.0288	CbGeAlD
Loxapine—HTR1D—artery—type 2 diabetes mellitus	0.000994	0.0284	CbGeAlD
Loxapine—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000871	0.0249	CbGeAlD
Loxapine—SLC6A2—nerve—type 2 diabetes mellitus	0.000815	0.0233	CbGeAlD
Loxapine—HTR2A—hindlimb—type 2 diabetes mellitus	0.000806	0.023	CbGeAlD
Loxapine—HTR7—artery—type 2 diabetes mellitus	0.000792	0.0226	CbGeAlD
Loxapine—HTR7—nerve—type 2 diabetes mellitus	0.000786	0.0224	CbGeAlD
Loxapine—DRD2—nerve—type 2 diabetes mellitus	0.000743	0.0212	CbGeAlD
Loxapine—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000739	0.0211	CbGeAlD
Loxapine—HTR7—endothelium—type 2 diabetes mellitus	0.000669	0.0191	CbGeAlD
Loxapine—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000628	0.0179	CbGeAlD
Loxapine—HTR3A—islet of Langerhans—type 2 diabetes mellitus	0.000588	0.0168	CbGeAlD
Loxapine—HRH2—cardiovascular system—type 2 diabetes mellitus	0.000541	0.0155	CbGeAlD
Loxapine—HTR2A—artery—type 2 diabetes mellitus	0.000494	0.0141	CbGeAlD
Loxapine—HTR2A—nerve—type 2 diabetes mellitus	0.00049	0.014	CbGeAlD
Loxapine—ADRA1B—kidney—type 2 diabetes mellitus	0.000462	0.0132	CbGeAlD
Loxapine—HTR2A—endothelium—type 2 diabetes mellitus	0.000417	0.0119	CbGeAlD
Loxapine—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000357	0.0102	CbGeAlD
Loxapine—CHRM2—cardiovascular system—type 2 diabetes mellitus	0.000355	0.0101	CbGeAlD
Loxapine—HTR1D—cardiovascular system—type 2 diabetes mellitus	0.000346	0.00986	CbGeAlD
Loxapine—HTR1D—kidney—type 2 diabetes mellitus	0.000338	0.00965	CbGeAlD
Loxapine—ADRB1—cardiovascular system—type 2 diabetes mellitus	0.000336	0.00959	CbGeAlD
Loxapine—HRH2—liver—type 2 diabetes mellitus	0.000335	0.00956	CbGeAlD
Loxapine—CHRM1—cardiovascular system—type 2 diabetes mellitus	0.000323	0.00922	CbGeAlD
Loxapine—DRD2—retina—type 2 diabetes mellitus	0.000308	0.00878	CbGeAlD
Loxapine—ADRB1—adipose tissue—type 2 diabetes mellitus	0.000296	0.00845	CbGeAlD
Loxapine—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000288	0.00822	CbGeAlD
Loxapine—CHRM3—kidney—type 2 diabetes mellitus	0.000283	0.00808	CbGeAlD
Loxapine—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000282	0.00804	CbGeAlD
Loxapine—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000279	0.00797	CbGeAlD
Loxapine—HTR7—cardiovascular system—type 2 diabetes mellitus	0.000275	0.00786	CbGeAlD
Loxapine—HTR7—kidney—type 2 diabetes mellitus	0.000269	0.00769	CbGeAlD
Loxapine—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000265	0.00758	CbGeAlD
Loxapine—CHRM3—adipose tissue—type 2 diabetes mellitus	0.000255	0.00728	CbGeAlD
Loxapine—ADRA2C—kidney—type 2 diabetes mellitus	0.000248	0.00707	CbGeAlD
Loxapine—ADRA2C—pancreas—type 2 diabetes mellitus	0.000246	0.00702	CbGeAlD
Loxapine—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000241	0.00688	CbGeAlD
Loxapine—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000234	0.00668	CbGeAlD
Loxapine—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000223	0.00637	CbGeAlD
Loxapine—Asenapine—ADRA2A—type 2 diabetes mellitus	0.000207	0.058	CrCbGaD
Loxapine—HTR2A—retina—type 2 diabetes mellitus	0.000203	0.00579	CbGeAlD
Loxapine—ADRA2A—pancreas—type 2 diabetes mellitus	0.000196	0.0056	CbGeAlD
Loxapine—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000192	0.00549	CbGeAlD
Loxapine—Asenapine—HTR2C—type 2 diabetes mellitus	0.00019	0.0534	CrCbGaD
Loxapine—HRH1—adipose tissue—type 2 diabetes mellitus	0.000181	0.00517	CbGeAlD
Loxapine—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000178	0.00508	CbGeAlD
Loxapine—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000172	0.0049	CbGeAlD
Loxapine—HTR7—liver—type 2 diabetes mellitus	0.00017	0.00486	CbGeAlD
Loxapine—HTR2A—kidney—type 2 diabetes mellitus	0.000168	0.00479	CbGeAlD
Loxapine—ADRA1A—liver—type 2 diabetes mellitus	0.000164	0.00469	CbGeAlD
Loxapine—Trifluoperazine—CALM1—type 2 diabetes mellitus	0.000159	0.0446	CrCbGaD
Loxapine—ADRA2C—liver—type 2 diabetes mellitus	0.000156	0.00447	CbGeAlD
Loxapine—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.00015	0.00123	CcSEcCtD
Loxapine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00015	0.00122	CcSEcCtD
Loxapine—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.000149	0.00122	CcSEcCtD
Loxapine—Muscle spasms—Metformin—type 2 diabetes mellitus	0.000149	0.00122	CcSEcCtD
Loxapine—Cough—Valsartan—type 2 diabetes mellitus	0.000148	0.00121	CcSEcCtD
Loxapine—Renal failure—Ramipril—type 2 diabetes mellitus	0.000148	0.00121	CcSEcCtD
Loxapine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000148	0.00121	CcSEcCtD
Loxapine—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000148	0.00121	CcSEcCtD
Loxapine—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	0.000148	0.00121	CcSEcCtD
Loxapine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000147	0.0012	CcSEcCtD
Loxapine—Jaundice—Ramipril—type 2 diabetes mellitus	0.000147	0.0012	CcSEcCtD
Loxapine—Cough—Orlistat—type 2 diabetes mellitus	0.000147	0.0012	CcSEcCtD
Loxapine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000146	0.0012	CcSEcCtD
Loxapine—Vision blurred—Metformin—type 2 diabetes mellitus	0.000146	0.00119	CcSEcCtD
Loxapine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000146	0.00119	CcSEcCtD
Loxapine—Convulsion—Orlistat—type 2 diabetes mellitus	0.000145	0.00119	CcSEcCtD
Loxapine—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000145	0.00119	CcSEcCtD
Loxapine—Tremor—Metformin—type 2 diabetes mellitus	0.000145	0.00119	CcSEcCtD
Loxapine—Chest pain—Valsartan—type 2 diabetes mellitus	0.000145	0.00118	CcSEcCtD
Loxapine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000144	0.00118	CcSEcCtD
Loxapine—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000144	0.00118	CcSEcCtD
Loxapine—Asenapine—CYP1A2—type 2 diabetes mellitus	0.000144	0.0403	CrCbGaD
Loxapine—Tension—Irbesartan—type 2 diabetes mellitus	0.000143	0.00117	CcSEcCtD
Loxapine—Angiopathy—Losartan—type 2 diabetes mellitus	0.000143	0.00117	CcSEcCtD
Loxapine—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000143	0.00117	CcSEcCtD
Loxapine—Chest pain—Orlistat—type 2 diabetes mellitus	0.000143	0.00117	CcSEcCtD
Loxapine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000141	0.00116	CcSEcCtD
Loxapine—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000141	0.00115	CcSEcCtD
Loxapine—Agranulocytosis—Ramipril—type 2 diabetes mellitus	0.000141	0.00115	CcSEcCtD
Loxapine—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.00014	0.00115	CcSEcCtD
Loxapine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.00014	0.00114	CcSEcCtD
Loxapine—Alopecia—Losartan—type 2 diabetes mellitus	0.00014	0.00114	CcSEcCtD
Loxapine—Vomiting—Glipizide—type 2 diabetes mellitus	0.000139	0.00114	CcSEcCtD
Loxapine—Syncope—Metformin—type 2 diabetes mellitus	0.000139	0.00113	CcSEcCtD
Loxapine—Oedema—Valsartan—type 2 diabetes mellitus	0.000139	0.00113	CcSEcCtD
Loxapine—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000139	0.00113	CcSEcCtD
Loxapine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000138	0.00113	CcSEcCtD
Loxapine—Rash—Glipizide—type 2 diabetes mellitus	0.000138	0.00113	CcSEcCtD
Loxapine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000138	0.00113	CcSEcCtD
Loxapine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000138	0.00113	CcSEcCtD
Loxapine—Oedema—Orlistat—type 2 diabetes mellitus	0.000137	0.00112	CcSEcCtD
Loxapine—Headache—Glipizide—type 2 diabetes mellitus	0.000137	0.00112	CcSEcCtD
Loxapine—Tremor—Irbesartan—type 2 diabetes mellitus	0.000137	0.00112	CcSEcCtD
Loxapine—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000137	0.00112	CcSEcCtD
Loxapine—Shock—Valsartan—type 2 diabetes mellitus	0.000136	0.00112	CcSEcCtD
Loxapine—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000136	0.00111	CcSEcCtD
Loxapine—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000136	0.00111	CcSEcCtD
Loxapine—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000136	0.00111	CcSEcCtD
Loxapine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000136	0.00111	CcSEcCtD
Loxapine—Hepatitis—Ramipril—type 2 diabetes mellitus	0.000135	0.00111	CcSEcCtD
Loxapine—Tension—Losartan—type 2 diabetes mellitus	0.000135	0.0011	CcSEcCtD
Loxapine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000135	0.0011	CcSEcCtD
Loxapine—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000135	0.0011	CcSEcCtD
Loxapine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000135	0.0011	CcSEcCtD
Loxapine—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000134	0.0011	CcSEcCtD
Loxapine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000134	0.0011	CcSEcCtD
Loxapine—Agitation—Irbesartan—type 2 diabetes mellitus	0.000134	0.0011	CcSEcCtD
Loxapine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000134	0.0011	CcSEcCtD
Loxapine—Hypertension—Metformin—type 2 diabetes mellitus	0.000134	0.00109	CcSEcCtD
Loxapine—Muscle spasms—Losartan—type 2 diabetes mellitus	0.000132	0.00108	CcSEcCtD
Loxapine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000132	0.00108	CcSEcCtD
Loxapine—Chest pain—Metformin—type 2 diabetes mellitus	0.000132	0.00108	CcSEcCtD
Loxapine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000131	0.00107	CcSEcCtD
Loxapine—Syncope—Irbesartan—type 2 diabetes mellitus	0.000131	0.00107	CcSEcCtD
Loxapine—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000131	0.00107	CcSEcCtD
Loxapine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00013	0.00107	CcSEcCtD
Loxapine—Fatigue—Gliclazide—type 2 diabetes mellitus	0.00013	0.00106	CcSEcCtD
Loxapine—Nausea—Glipizide—type 2 diabetes mellitus	0.00013	0.00106	CcSEcCtD
Loxapine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00013	0.00106	CcSEcCtD
Loxapine—Hypotension—Valsartan—type 2 diabetes mellitus	0.00013	0.00106	CcSEcCtD
Loxapine—Vision blurred—Losartan—type 2 diabetes mellitus	0.00013	0.00106	CcSEcCtD
Loxapine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000129	0.00106	CcSEcCtD
Loxapine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000129	0.00106	CcSEcCtD
Loxapine—Tremor—Losartan—type 2 diabetes mellitus	0.000129	0.00105	CcSEcCtD
Loxapine—Rash—Glimepiride—type 2 diabetes mellitus	0.000129	0.00105	CcSEcCtD
Loxapine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000128	0.00105	CcSEcCtD
Loxapine—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000128	0.00105	CcSEcCtD
Loxapine—Rash—Sitagliptin—type 2 diabetes mellitus	0.000128	0.00105	CcSEcCtD
Loxapine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000128	0.00105	CcSEcCtD
Loxapine—Headache—Glimepiride—type 2 diabetes mellitus	0.000128	0.00104	CcSEcCtD
Loxapine—Cough—Irbesartan—type 2 diabetes mellitus	0.000127	0.00104	CcSEcCtD
Loxapine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000127	0.00104	CcSEcCtD
Loxapine—Agitation—Losartan—type 2 diabetes mellitus	0.000126	0.00103	CcSEcCtD
Loxapine—Oedema—Metformin—type 2 diabetes mellitus	0.000126	0.00103	CcSEcCtD
Loxapine—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000126	0.00103	CcSEcCtD
Loxapine—Insomnia—Valsartan—type 2 diabetes mellitus	0.000125	0.00103	CcSEcCtD
Loxapine—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000125	0.00102	CcSEcCtD
Loxapine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000124	0.00102	CcSEcCtD
Loxapine—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000124	0.00102	CcSEcCtD
Loxapine—Shock—Metformin—type 2 diabetes mellitus	0.000124	0.00102	CcSEcCtD
Loxapine—Insomnia—Orlistat—type 2 diabetes mellitus	0.000124	0.00101	CcSEcCtD
Loxapine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000124	0.00101	CcSEcCtD
Loxapine—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000124	0.00101	CcSEcCtD
Loxapine—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000124	0.00101	CcSEcCtD
Loxapine—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000124	0.00101	CcSEcCtD
Loxapine—Azatadine—CYP3A4—type 2 diabetes mellitus	0.000124	0.0347	CrCbGaD
Loxapine—Somnolence—Valsartan—type 2 diabetes mellitus	0.000123	0.00101	CcSEcCtD
Loxapine—Syncope—Losartan—type 2 diabetes mellitus	0.000123	0.00101	CcSEcCtD
Loxapine—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000123	0.00101	CcSEcCtD
Loxapine—Leukopenia—Losartan—type 2 diabetes mellitus	0.000123	0.00101	CcSEcCtD
Loxapine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000122	0.000998	CcSEcCtD
Loxapine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000122	0.000994	CcSEcCtD
Loxapine—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000122	0.000994	CcSEcCtD
Loxapine—Nausea—Glimepiride—type 2 diabetes mellitus	0.000121	0.00099	CcSEcCtD
Loxapine—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000121	0.000988	CcSEcCtD
Loxapine—Zuclopenthixol—ADRA2A—type 2 diabetes mellitus	0.000121	0.0339	CrCbGaD
Loxapine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000121	0.000987	CcSEcCtD
Loxapine—Asthenia—Glyburide—type 2 diabetes mellitus	0.000121	0.000986	CcSEcCtD
Loxapine—Cough—Losartan—type 2 diabetes mellitus	0.00012	0.000981	CcSEcCtD
Loxapine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.00012	0.000979	CcSEcCtD
Loxapine—Alopecia—Ramipril—type 2 diabetes mellitus	0.00012	0.000978	CcSEcCtD
Loxapine—Fatigue—Valsartan—type 2 diabetes mellitus	0.00012	0.000978	CcSEcCtD
Loxapine—Oedema—Irbesartan—type 2 diabetes mellitus	0.000119	0.000975	CcSEcCtD
Loxapine—Pruritus—Glyburide—type 2 diabetes mellitus	0.000119	0.000972	CcSEcCtD
Loxapine—Constipation—Valsartan—type 2 diabetes mellitus	0.000119	0.00097	CcSEcCtD
Loxapine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000118	0.000967	CcSEcCtD
Loxapine—Fatigue—Orlistat—type 2 diabetes mellitus	0.000118	0.000966	CcSEcCtD
Loxapine—Hypotension—Metformin—type 2 diabetes mellitus	0.000118	0.000965	CcSEcCtD
Loxapine—Shock—Irbesartan—type 2 diabetes mellitus	0.000117	0.000959	CcSEcCtD
Loxapine—Chest pain—Losartan—type 2 diabetes mellitus	0.000117	0.000957	CcSEcCtD
Loxapine—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000117	0.000956	CcSEcCtD
Loxapine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000117	0.000956	CcSEcCtD
Loxapine—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000117	0.000954	CcSEcCtD
Loxapine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000116	0.000951	CcSEcCtD
Loxapine—Rash—Bromocriptine—type 2 diabetes mellitus	0.000116	0.000948	CcSEcCtD
Loxapine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000116	0.000947	CcSEcCtD
Loxapine—Tension—Ramipril—type 2 diabetes mellitus	0.000116	0.000946	CcSEcCtD
Loxapine—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000115	0.000944	CcSEcCtD
Loxapine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000115	0.000942	CcSEcCtD
Loxapine—Olanzapine—ADRA2A—type 2 diabetes mellitus	0.000115	0.0323	CrCbGaD
Loxapine—Dry mouth—Losartan—type 2 diabetes mellitus	0.000114	0.000936	CcSEcCtD
Loxapine—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000113	0.000927	CcSEcCtD
Loxapine—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000113	0.000926	CcSEcCtD
Loxapine—Confusional state—Losartan—type 2 diabetes mellitus	0.000113	0.000925	CcSEcCtD
Loxapine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000113	0.000923	CcSEcCtD
Loxapine—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000113	0.000921	CcSEcCtD
Loxapine—Somnolence—Metformin—type 2 diabetes mellitus	0.000112	0.000918	CcSEcCtD
Loxapine—Oedema—Losartan—type 2 diabetes mellitus	0.000112	0.000917	CcSEcCtD
Loxapine—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000111	0.000911	CcSEcCtD
Loxapine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000111	0.000909	CcSEcCtD
Loxapine—Trazodone—ADRA2A—type 2 diabetes mellitus	0.000111	0.0312	CrCbGaD
Loxapine—Tremor—Ramipril—type 2 diabetes mellitus	0.00011	0.000903	CcSEcCtD
Loxapine—Shock—Losartan—type 2 diabetes mellitus	0.00011	0.000902	CcSEcCtD
Loxapine—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00011	0.000899	CcSEcCtD
Loxapine—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.00011	0.000898	CcSEcCtD
Loxapine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000109	0.000895	CcSEcCtD
Loxapine—Cyproheptadine—HTR2C—type 2 diabetes mellitus	0.000109	0.0307	CrCbGaD
Loxapine—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000109	0.000893	CcSEcCtD
Loxapine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000109	0.000892	CcSEcCtD
Loxapine—Fatigue—Metformin—type 2 diabetes mellitus	0.000109	0.00089	CcSEcCtD
Loxapine—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000108	0.000886	CcSEcCtD
Loxapine—Agitation—Ramipril—type 2 diabetes mellitus	0.000108	0.000885	CcSEcCtD
Loxapine—Constipation—Metformin—type 2 diabetes mellitus	0.000108	0.000883	CcSEcCtD
Loxapine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000107	0.000875	CcSEcCtD
Loxapine—Vomiting—Glyburide—type 2 diabetes mellitus	0.000107	0.000874	CcSEcCtD
Loxapine—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000107	0.000873	CcSEcCtD
Loxapine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000106	0.000869	CcSEcCtD
Loxapine—HTR2A—liver—type 2 diabetes mellitus	0.000106	0.00303	CbGeAlD
Loxapine—Rash—Glyburide—type 2 diabetes mellitus	0.000106	0.000867	CcSEcCtD
Loxapine—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000106	0.000866	CcSEcCtD
Loxapine—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000106	0.000866	CcSEcCtD
Loxapine—Olanzapine—HTR2C—type 2 diabetes mellitus	0.000106	0.0297	CrCbGaD
Loxapine—Syncope—Ramipril—type 2 diabetes mellitus	0.000106	0.000864	CcSEcCtD
Loxapine—Leukopenia—Ramipril—type 2 diabetes mellitus	0.000105	0.000862	CcSEcCtD
Loxapine—Headache—Glyburide—type 2 diabetes mellitus	0.000105	0.000861	CcSEcCtD
Loxapine—Hypotension—Losartan—type 2 diabetes mellitus	0.000105	0.000857	CcSEcCtD
Loxapine—Thiothixene—ADRA2A—type 2 diabetes mellitus	0.000104	0.0292	CrCbGaD
Loxapine—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000104	0.000851	CcSEcCtD
Loxapine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000104	0.000847	CcSEcCtD
Loxapine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000103	0.000841	CcSEcCtD
Loxapine—Cough—Ramipril—type 2 diabetes mellitus	0.000103	0.000841	CcSEcCtD
Loxapine—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000103	0.00084	CcSEcCtD
Loxapine—Trazodone—HTR2C—type 2 diabetes mellitus	0.000102	0.0287	CrCbGaD
Loxapine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000102	0.000835	CcSEcCtD
Loxapine—Convulsion—Ramipril—type 2 diabetes mellitus	0.000102	0.000835	CcSEcCtD
Loxapine—Constipation—Irbesartan—type 2 diabetes mellitus	0.000102	0.000833	CcSEcCtD
Loxapine—Insomnia—Losartan—type 2 diabetes mellitus	0.000101	0.000829	CcSEcCtD
Loxapine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000101	0.000826	CcSEcCtD
Loxapine—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000101	0.000824	CcSEcCtD
Loxapine—Chest pain—Ramipril—type 2 diabetes mellitus	0.0001	0.00082	CcSEcCtD
Loxapine—Dyspnoea—Losartan—type 2 diabetes mellitus	0.0001	0.000818	CcSEcCtD
Loxapine—Nausea—Glyburide—type 2 diabetes mellitus	9.99e-05	0.000816	CcSEcCtD
Loxapine—Dizziness—Gliclazide—type 2 diabetes mellitus	9.98e-05	0.000816	CcSEcCtD
Loxapine—Somnolence—Losartan—type 2 diabetes mellitus	9.97e-05	0.000815	CcSEcCtD
Loxapine—Asthenia—Valsartan—type 2 diabetes mellitus	9.95e-05	0.000814	CcSEcCtD
Loxapine—Asthenia—Orlistat—type 2 diabetes mellitus	9.83e-05	0.000804	CcSEcCtD
Loxapine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	9.82e-05	0.000803	CcSEcCtD
Loxapine—Pruritus—Valsartan—type 2 diabetes mellitus	9.81e-05	0.000802	CcSEcCtD
Loxapine—Dry mouth—Ramipril—type 2 diabetes mellitus	9.81e-05	0.000802	CcSEcCtD
Loxapine—Azelastine—CYP2E1—type 2 diabetes mellitus	9.78e-05	0.0274	CrCbGaD
Loxapine—Confusional state—Ramipril—type 2 diabetes mellitus	9.7e-05	0.000793	CcSEcCtD
Loxapine—Pruritus—Orlistat—type 2 diabetes mellitus	9.7e-05	0.000793	CcSEcCtD
Loxapine—Fatigue—Losartan—type 2 diabetes mellitus	9.67e-05	0.000791	CcSEcCtD
Loxapine—Oedema—Ramipril—type 2 diabetes mellitus	9.62e-05	0.000786	CcSEcCtD
Loxapine—Vomiting—Gliclazide—type 2 diabetes mellitus	9.6e-05	0.000785	CcSEcCtD
Loxapine—Constipation—Losartan—type 2 diabetes mellitus	9.59e-05	0.000784	CcSEcCtD
Loxapine—Thiothixene—HTR2C—type 2 diabetes mellitus	9.59e-05	0.0269	CrCbGaD
Loxapine—Rash—Gliclazide—type 2 diabetes mellitus	9.52e-05	0.000778	CcSEcCtD
Loxapine—Dermatitis—Gliclazide—type 2 diabetes mellitus	9.51e-05	0.000777	CcSEcCtD
Loxapine—Asenapine—CYP3A4—type 2 diabetes mellitus	9.51e-05	0.0267	CrCbGaD
Loxapine—Shock—Ramipril—type 2 diabetes mellitus	9.46e-05	0.000774	CcSEcCtD
Loxapine—Headache—Gliclazide—type 2 diabetes mellitus	9.46e-05	0.000773	CcSEcCtD
Loxapine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	9.43e-05	0.000771	CcSEcCtD
Loxapine—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	9.42e-05	0.00077	CcSEcCtD
Loxapine—Tachycardia—Ramipril—type 2 diabetes mellitus	9.39e-05	0.000767	CcSEcCtD
Loxapine—Azelastine—CYP1A2—type 2 diabetes mellitus	9.3e-05	0.0261	CrCbGaD
Loxapine—Feeling abnormal—Losartan—type 2 diabetes mellitus	9.24e-05	0.000756	CcSEcCtD
Loxapine—Dizziness—Valsartan—type 2 diabetes mellitus	9.17e-05	0.00075	CcSEcCtD
Loxapine—Prochlorperazine—HTR2C—type 2 diabetes mellitus	9.16e-05	0.0257	CrCbGaD
Loxapine—Amoxapine—ADRA2A—type 2 diabetes mellitus	9.15e-05	0.0257	CrCbGaD
Loxapine—Dizziness—Orlistat—type 2 diabetes mellitus	9.06e-05	0.000741	CcSEcCtD
Loxapine—Asthenia—Metformin—type 2 diabetes mellitus	9.06e-05	0.000741	CcSEcCtD
Loxapine—Hypotension—Ramipril—type 2 diabetes mellitus	8.99e-05	0.000735	CcSEcCtD
Loxapine—Nausea—Gliclazide—type 2 diabetes mellitus	8.97e-05	0.000733	CcSEcCtD
Loxapine—Pruritus—Metformin—type 2 diabetes mellitus	8.94e-05	0.000731	CcSEcCtD
Loxapine—Vomiting—Valsartan—type 2 diabetes mellitus	8.82e-05	0.000721	CcSEcCtD
Loxapine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	8.78e-05	0.000718	CcSEcCtD
Loxapine—Rash—Valsartan—type 2 diabetes mellitus	8.74e-05	0.000715	CcSEcCtD
Loxapine—Dermatitis—Valsartan—type 2 diabetes mellitus	8.74e-05	0.000714	CcSEcCtD
Loxapine—Vomiting—Orlistat—type 2 diabetes mellitus	8.71e-05	0.000712	CcSEcCtD
Loxapine—Insomnia—Ramipril—type 2 diabetes mellitus	8.7e-05	0.000711	CcSEcCtD
Loxapine—Headache—Valsartan—type 2 diabetes mellitus	8.69e-05	0.00071	CcSEcCtD
Loxapine—Rash—Orlistat—type 2 diabetes mellitus	8.64e-05	0.000706	CcSEcCtD
Loxapine—Paraesthesia—Ramipril—type 2 diabetes mellitus	8.64e-05	0.000706	CcSEcCtD
Loxapine—Dermatitis—Orlistat—type 2 diabetes mellitus	8.63e-05	0.000706	CcSEcCtD
Loxapine—Headache—Orlistat—type 2 diabetes mellitus	8.59e-05	0.000702	CcSEcCtD
Loxapine—Dyspnoea—Ramipril—type 2 diabetes mellitus	8.57e-05	0.000701	CcSEcCtD
Loxapine—Asthenia—Irbesartan—type 2 diabetes mellitus	8.55e-05	0.000699	CcSEcCtD
Loxapine—Somnolence—Ramipril—type 2 diabetes mellitus	8.55e-05	0.000699	CcSEcCtD
Loxapine—Pruritus—Irbesartan—type 2 diabetes mellitus	8.43e-05	0.000689	CcSEcCtD
Loxapine—Amoxapine—HTR2C—type 2 diabetes mellitus	8.43e-05	0.0236	CrCbGaD
Loxapine—Dizziness—Metformin—type 2 diabetes mellitus	8.35e-05	0.000683	CcSEcCtD
Loxapine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	8.3e-05	0.000679	CcSEcCtD
Loxapine—Fatigue—Ramipril—type 2 diabetes mellitus	8.29e-05	0.000678	CcSEcCtD
Loxapine—Hypersensitivity—Losartan—type 2 diabetes mellitus	8.26e-05	0.000676	CcSEcCtD
Loxapine—Nausea—Valsartan—type 2 diabetes mellitus	8.24e-05	0.000674	CcSEcCtD
Loxapine—Constipation—Ramipril—type 2 diabetes mellitus	8.22e-05	0.000672	CcSEcCtD
Loxapine—Nausea—Orlistat—type 2 diabetes mellitus	8.14e-05	0.000666	CcSEcCtD
Loxapine—Asthenia—Losartan—type 2 diabetes mellitus	8.05e-05	0.000658	CcSEcCtD
Loxapine—Vomiting—Metformin—type 2 diabetes mellitus	8.03e-05	0.000657	CcSEcCtD
Loxapine—Olanzapine—CYP1A2—type 2 diabetes mellitus	7.99e-05	0.0224	CrCbGaD
Loxapine—Rash—Metformin—type 2 diabetes mellitus	7.96e-05	0.000651	CcSEcCtD
Loxapine—Dermatitis—Metformin—type 2 diabetes mellitus	7.96e-05	0.00065	CcSEcCtD
Loxapine—Pruritus—Losartan—type 2 diabetes mellitus	7.94e-05	0.000649	CcSEcCtD
Loxapine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	7.93e-05	0.000648	CcSEcCtD
Loxapine—Headache—Metformin—type 2 diabetes mellitus	7.91e-05	0.000647	CcSEcCtD
Loxapine—Dizziness—Irbesartan—type 2 diabetes mellitus	7.88e-05	0.000644	CcSEcCtD
Loxapine—Vomiting—Irbesartan—type 2 diabetes mellitus	7.58e-05	0.00062	CcSEcCtD
Loxapine—Rash—Irbesartan—type 2 diabetes mellitus	7.52e-05	0.000614	CcSEcCtD
Loxapine—Dermatitis—Irbesartan—type 2 diabetes mellitus	7.51e-05	0.000614	CcSEcCtD
Loxapine—Nausea—Metformin—type 2 diabetes mellitus	7.5e-05	0.000613	CcSEcCtD
Loxapine—Headache—Irbesartan—type 2 diabetes mellitus	7.47e-05	0.00061	CcSEcCtD
Loxapine—Dizziness—Losartan—type 2 diabetes mellitus	7.42e-05	0.000606	CcSEcCtD
Loxapine—Thiothixene—CYP1A2—type 2 diabetes mellitus	7.23e-05	0.0203	CrCbGaD
Loxapine—Vomiting—Losartan—type 2 diabetes mellitus	7.13e-05	0.000583	CcSEcCtD
Loxapine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	7.09e-05	0.000579	CcSEcCtD
Loxapine—Nausea—Irbesartan—type 2 diabetes mellitus	7.08e-05	0.000579	CcSEcCtD
Loxapine—Rash—Losartan—type 2 diabetes mellitus	7.07e-05	0.000578	CcSEcCtD
Loxapine—Dermatitis—Losartan—type 2 diabetes mellitus	7.07e-05	0.000578	CcSEcCtD
Loxapine—Headache—Losartan—type 2 diabetes mellitus	7.03e-05	0.000575	CcSEcCtD
Loxapine—Quetiapine—ADRA2A—type 2 diabetes mellitus	6.98e-05	0.0196	CrCbGaD
Loxapine—Asthenia—Ramipril—type 2 diabetes mellitus	6.9e-05	0.000564	CcSEcCtD
Loxapine—Pruritus—Ramipril—type 2 diabetes mellitus	6.8e-05	0.000556	CcSEcCtD
Loxapine—Nausea—Losartan—type 2 diabetes mellitus	6.66e-05	0.000545	CcSEcCtD
Loxapine—Trifluoperazine—HTR2C—type 2 diabetes mellitus	6.62e-05	0.0186	CrCbGaD
Loxapine—Quetiapine—HTR2C—type 2 diabetes mellitus	6.42e-05	0.018	CrCbGaD
Loxapine—Dizziness—Ramipril—type 2 diabetes mellitus	6.36e-05	0.00052	CcSEcCtD
Loxapine—Azelastine—CYP3A4—type 2 diabetes mellitus	6.16e-05	0.0173	CrCbGaD
Loxapine—Vomiting—Ramipril—type 2 diabetes mellitus	6.12e-05	0.0005	CcSEcCtD
Loxapine—Rash—Ramipril—type 2 diabetes mellitus	6.06e-05	0.000496	CcSEcCtD
Loxapine—Dermatitis—Ramipril—type 2 diabetes mellitus	6.06e-05	0.000495	CcSEcCtD
Loxapine—Headache—Ramipril—type 2 diabetes mellitus	6.03e-05	0.000493	CcSEcCtD
Loxapine—Clozapine—ADRA2A—type 2 diabetes mellitus	6e-05	0.0168	CrCbGaD
Loxapine—Nausea—Ramipril—type 2 diabetes mellitus	5.71e-05	0.000467	CcSEcCtD
Loxapine—Chlordiazepoxide—CYP3A4—type 2 diabetes mellitus	5.65e-05	0.0159	CrCbGaD
Loxapine—Clozapine—HTR2C—type 2 diabetes mellitus	5.53e-05	0.0155	CrCbGaD
Loxapine—Olanzapine—CYP3A4—type 2 diabetes mellitus	5.29e-05	0.0148	CrCbGaD
Loxapine—Trazodone—CYP3A4—type 2 diabetes mellitus	5.11e-05	0.0143	CrCbGaD
Loxapine—Trifluoperazine—CYP1A2—type 2 diabetes mellitus	5e-05	0.014	CrCbGaD
Loxapine—Alprazolam—CYP3A4—type 2 diabetes mellitus	4.79e-05	0.0134	CrCbGaD
Loxapine—Clobazam—CYP3A4—type 2 diabetes mellitus	4.79e-05	0.0134	CrCbGaD
Loxapine—Olanzapine—ALB—type 2 diabetes mellitus	4.61e-05	0.0129	CrCbGaD
Loxapine—Prochlorperazine—CYP3A4—type 2 diabetes mellitus	4.58e-05	0.0128	CrCbGaD
Loxapine—Diazepam—CYP2E1—type 2 diabetes mellitus	4.44e-05	0.0124	CrCbGaD
Loxapine—Clozapine—CYP2E1—type 2 diabetes mellitus	4.38e-05	0.0123	CrCbGaD
Loxapine—Diazepam—CYP1A2—type 2 diabetes mellitus	4.22e-05	0.0118	CrCbGaD
Loxapine—Thiothixene—ALB—type 2 diabetes mellitus	4.18e-05	0.0117	CrCbGaD
Loxapine—Clozapine—CYP1A2—type 2 diabetes mellitus	4.17e-05	0.0117	CrCbGaD
Loxapine—Prazepam—CYP3A4—type 2 diabetes mellitus	3.77e-05	0.0106	CrCbGaD
Loxapine—Temazepam—CYP3A4—type 2 diabetes mellitus	3.36e-05	0.00944	CrCbGaD
Loxapine—Quetiapine—CYP3A4—type 2 diabetes mellitus	3.21e-05	0.009	CrCbGaD
Loxapine—Diazepam—CYP3A4—type 2 diabetes mellitus	2.8e-05	0.00784	CrCbGaD
Loxapine—Clozapine—CYP3A4—type 2 diabetes mellitus	2.76e-05	0.00774	CrCbGaD
Loxapine—Diazepam—ALB—type 2 diabetes mellitus	2.44e-05	0.00684	CrCbGaD
Loxapine—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.25e-06	1.04e-05	CbGpPWpGaD
Loxapine—ADRB1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.25e-06	1.04e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.25e-06	1.04e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.25e-06	1.04e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.25e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.24e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.24e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.24e-06	1.03e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.24e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.24e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.23e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.23e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.23e-06	1.02e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.23e-06	1.02e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.23e-06	1.02e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.23e-06	1.02e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.23e-06	1.02e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.22e-06	1.02e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.22e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.22e-06	1.02e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.22e-06	1.01e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.22e-06	1.01e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.21e-06	1.01e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.21e-06	1.01e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.21e-06	1.01e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.21e-06	1e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.21e-06	1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.21e-06	1e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.21e-06	1e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.21e-06	1e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.2e-06	1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	1.2e-06	1e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.2e-06	9.99e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.2e-06	9.99e-06	CbGpPWpGaD
Loxapine—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.2e-06	9.97e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.2e-06	9.96e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.2e-06	9.96e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.19e-06	9.93e-06	CbGpPWpGaD
Loxapine—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.19e-06	9.91e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.19e-06	9.9e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.19e-06	9.87e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—SRC—type 2 diabetes mellitus	1.19e-06	9.87e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.19e-06	9.86e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.19e-06	9.86e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.18e-06	9.84e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.18e-06	9.84e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.18e-06	9.82e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.18e-06	9.81e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.18e-06	9.8e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.17e-06	9.76e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.17e-06	9.75e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.17e-06	9.74e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.17e-06	9.74e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.16e-06	9.67e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.16e-06	9.65e-06	CbGpPWpGaD
Loxapine—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.16e-06	9.64e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.16e-06	9.61e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.16e-06	9.61e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.15e-06	9.61e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.15e-06	9.57e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.15e-06	9.56e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.15e-06	9.55e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.14e-06	9.49e-06	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.14e-06	9.49e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.14e-06	9.46e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.14e-06	9.46e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.13e-06	9.44e-06	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.13e-06	9.42e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.13e-06	9.41e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.13e-06	9.4e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.13e-06	9.38e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	1.13e-06	9.38e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.13e-06	9.37e-06	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.12e-06	9.36e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.12e-06	9.34e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.12e-06	9.33e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	1.12e-06	9.29e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.12e-06	9.28e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.11e-06	9.26e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.11e-06	9.23e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.11e-06	9.2e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.1e-06	9.18e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.1e-06	9.14e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.1e-06	9.14e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.09e-06	9.05e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.09e-06	9.03e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.08e-06	9e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.08e-06	8.99e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.07e-06	8.94e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.07e-06	8.93e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.07e-06	8.91e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.07e-06	8.89e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.06e-06	8.82e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.06e-06	8.79e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.05e-06	8.77e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.05e-06	8.76e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.05e-06	8.76e-06	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.05e-06	8.75e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.04e-06	8.68e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.04e-06	8.67e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.04e-06	8.65e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.04e-06	8.62e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.04e-06	8.61e-06	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.03e-06	8.61e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.03e-06	8.6e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.03e-06	8.6e-06	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.03e-06	8.59e-06	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.03e-06	8.56e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.03e-06	8.56e-06	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.03e-06	8.54e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.03e-06	8.53e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.02e-06	8.51e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.02e-06	8.48e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.02e-06	8.47e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.02e-06	8.46e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.02e-06	8.46e-06	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.02e-06	8.45e-06	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.01e-06	8.43e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.01e-06	8.43e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.01e-06	8.4e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.01e-06	8.38e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.01e-06	8.38e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1e-06	8.35e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1e-06	8.34e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1e-06	8.32e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	1e-06	8.32e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.97e-07	8.3e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	9.85e-07	8.19e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.85e-07	8.19e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.75e-07	8.11e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.74e-07	8.11e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.69e-07	8.06e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.67e-07	8.04e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.66e-07	8.04e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.64e-07	8.02e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.61e-07	7.99e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.59e-07	7.98e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.59e-07	7.98e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.58e-07	7.97e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.57e-07	7.96e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.55e-07	7.95e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.53e-07	7.93e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.51e-07	7.91e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.5e-07	7.91e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.49e-07	7.89e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.48e-07	7.88e-06	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.41e-07	7.83e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.41e-07	7.83e-06	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—type 2 diabetes mellitus	9.41e-07	7.83e-06	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—type 2 diabetes mellitus	9.4e-07	7.82e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.4e-07	7.82e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.39e-07	7.81e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.39e-07	7.81e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.38e-07	7.8e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.35e-07	7.78e-06	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	9.34e-07	7.77e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.33e-07	7.76e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.32e-07	7.75e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.27e-07	7.71e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.24e-07	7.69e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.23e-07	7.68e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.2e-07	7.66e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.2e-07	7.65e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	9.14e-07	7.61e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	9.08e-07	7.55e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.06e-07	7.54e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.02e-07	7.5e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—type 2 diabetes mellitus	9e-07	7.49e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.94e-07	7.44e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	8.93e-07	7.43e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SRC—type 2 diabetes mellitus	8.91e-07	7.42e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	8.89e-07	7.39e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	8.88e-07	7.38e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	8.86e-07	7.37e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.84e-07	7.36e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.81e-07	7.33e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.8e-07	7.32e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	8.77e-07	7.3e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.77e-07	7.3e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	8.75e-07	7.28e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.72e-07	7.26e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.7e-07	7.24e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.68e-07	7.22e-06	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.68e-07	7.22e-06	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.67e-07	7.21e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.65e-07	7.2e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.63e-07	7.18e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.63e-07	7.18e-06	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.61e-07	7.17e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.55e-07	7.11e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.54e-07	7.11e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.52e-07	7.09e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	8.5e-07	7.07e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.44e-07	7.02e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.3e-07	6.91e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.19e-07	6.81e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	8.13e-07	6.76e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.12e-07	6.75e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	8.1e-07	6.74e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—type 2 diabetes mellitus	7.99e-07	6.65e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.99e-07	6.64e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.97e-07	6.63e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.96e-07	6.62e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.94e-07	6.61e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.92e-07	6.59e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.92e-07	6.59e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.84e-07	6.52e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.84e-07	6.52e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.83e-07	6.51e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.82e-07	6.51e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.81e-07	6.5e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.79e-07	6.48e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.76e-07	6.46e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.69e-07	6.4e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.67e-07	6.38e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.47e-07	6.22e-06	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	7.44e-07	6.19e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.37e-07	6.13e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—type 2 diabetes mellitus	7.28e-07	6.06e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.27e-07	6.04e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	7.22e-07	6e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.12e-07	5.93e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.97e-07	5.79e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	6.93e-07	5.77e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	6.74e-07	5.61e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.72e-07	5.59e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.66e-07	5.54e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	6.63e-07	5.52e-06	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	6.58e-07	5.48e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.43e-07	5.35e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.39e-07	5.32e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.22e-07	5.17e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.12e-07	5.09e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	6.12e-07	5.09e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	6.04e-07	5.02e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.02e-07	5.01e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—type 2 diabetes mellitus	6e-07	5e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.99e-07	4.98e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	5.97e-07	4.96e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.91e-07	4.92e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	5.89e-07	4.9e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.64e-07	4.69e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.55e-07	4.62e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.54e-07	4.61e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.52e-07	4.59e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.5e-07	4.58e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	5.47e-07	4.55e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.45e-07	4.53e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.44e-07	4.52e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.05e-07	4.2e-06	CbGpPWpGaD
